HIV Infections research hub

A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Adaptive Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in Treatment-Naïve Adults Living with HIV-1

This study is testing a new medicine, VH3739937, for people recently diagnosed with HIV. We want to see how well it lowers the amount of virus in the blood and if it's safe to use. Some participants will receive a dummy pill (placebo) instead of the actual medicine.

A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults

This study is testing a new medicine, VH4524184, for adults who have HIV-1 but haven't started treatment yet. We want to see how well it fights the virus, if it's safe to use, and how the body handles it. It's an early-stage study to understand its effects.

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

This study looks at whether switching from daily tablets to monthly injections can keep HIV under control in adults. It's for people whose HIV is already well-managed with current medication, testing a new long-acting injectable treatment.

HIV and Changes in the Gut Microbiome After Changes in Antiretroviral Therapy (ART)

This study looks at how HIV medicine affects the 'good' bacteria in our gut. Researchers want to see if changing HIV treatment also changes these gut bacteria. Understanding this could help doctors choose the best treatment for each person.

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

This study looks at a new drug (BMS-663068) for people with HIV-1 who have tried many treatments and whose current medication isn’t working well. It wants to see if this new drug can help them, especially if their HIV has become resistant to other medicines.

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

This study looks at two different daily pill combinations for adults newly diagnosed with HIV. It compares a two-drug treatment with a three-drug treatment to see which is safer and works better for controlling the virus.

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

This study looks at new ways to reduce the amount of hidden HIV in the body. It tests a new drug, VH3810109, with or without an existing drug, Fostemsavir, in people with HIV who are new to treatment or are already on treatment.

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

This study looks at how HIV medicines work in pregnant women. Pregnancy can change how the body handles medicines, so researchers want to ensure the current doses are still effective for both mother and baby. We're studying several common HIV drugs.

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

This study looks at new ways to treat HIV in children. It's testing if certain medicines (ATV/co, DRV/co, F/TAF) are safe and work well for children aged 4 weeks to 17 years. The goal is to find better treatment options for young people living with HIV.

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old

This study looks at a two-drug treatment (Dolutegravir and Lamivudine) for children and young people with HIV, aged 2 to 15. It aims to see if it's as safe and effective as their current three-drug therapy.

A Randomized, Double-Blind, Placebo-Controlled, Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Orally Administered Capsid Inhibitors in HIV-1 Infected Treatment-Naïve Adults